ABBV · News · 20260828N
Regulatory Approval Milestones
AbbVie Inc. · 2026-08-28 · Importance 31 · Surprise 42 · In source text
AbbVie is seeking European Union approval for a subcutaneous induction option of Skyrizi (risankizumab) for Crohn’s disease. The proposed option could provide patients with a more convenient administration route during induction treatment. The report does not disclose a filing date, approval decision timeframe, or estimated financial impact.
Key facts
- AbbVie seeks EU approval for a subcutaneous Skyrizi induction option in Crohn's disease. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | AbbVie seeks EU approval for a subcutaneous Skyrizi induction option in Crohn's disease. |